AIM ImmunoTech Accelerates Pancreatic Cancer Trial Enrollment, Eyes Key Data Readout
Event summary
- AIM ImmunoTech completed Phase 2 DURIPANC trial enrollment ahead of schedule in June 2026, originally targeted for July.
- The study evaluates Ampligen combined with AstraZeneca's Imfinzi for metastatic pancreatic cancer patients.
- Primary endpoint evaluation for Clinical Benefit Rate is planned for December 2026.
- Company reports encouraging survival outcomes and strong safety profile from interim results.
- Phase 3 trial planning is underway, supported by positive data from over 100 pancreatic cancer patients treated with Ampligen.
The big picture
AIM's accelerated enrollment in the DURIPANC trial positions Ampligen as a potential breakthrough in pancreatic cancer treatment, an area with high unmet medical need. The company's strategic focus on combination therapies and global regulatory positioning could enhance its competitive edge in oncology. Pancreatic cancer's rising mortality rate underscores the urgency for innovative treatments, making this trial a critical inflection point for AIM.
What we're watching
- Clinical Efficacy
- Whether Ampligen's combination therapy can demonstrate meaningful improvement in Clinical Benefit Rate for pancreatic cancer patients.
- Regulatory Pathway
- The pace at which AIM advances toward pivotal-stage development and secures orphan drug designations.
- Competitive Positioning
- How AIM differentiates Ampligen in the pancreatic cancer treatment landscape amid limited therapeutic options.
Related topics